Recruiting

MagnetOs Putty

Sponsor:

Kuros Biosurgery AG

Code:

NCT04679844

Conditions

Degenerative Disc Disease

Spine Fusion

Back Pain

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MagnetOs Easypack Putty

Demineralized Bone Matrix or Fibers mixed with local autograft bone

Study Details

Brief summary:

This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.

In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.

Conditions

Degenerative Disc Disease

Spine Fusion

Back Pain

Study ID

NCT04679844

Start date

Dec 6, 2024

Status verified date

Nov, 2025

Completion date

Aug 30, 2027

Anticipated

Primary completion date

Jun 2, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
  • Male or female patient ≥ 18 years old.
  • Patients with segmental mechanical spinal instability requiring arthrodesis surgery.

Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:

1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
2. decreased disc height by > 2 mm, but dependent upon the spinal level
3. Grade II or more listhesis
4. TLICS equal or greater than 5
5. Unstable burst fracture

  • Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.

Exclusion Criteria:

  • Requires > two-level fusion or expected to need secondary intervention within one year following surgery.
  • Had prior PLF fusion or attempted PLF fusion at the involved levels.
  • Had previous decompression at the involved levels.
  • Women who are or intend to become pregnant within the next 12 months.
  • To treat conditions in which general bone grafting is not advisable.
  • In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
  • In case of significant vascular impairment proximal to the graft site.
  • In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage >4 renal disease or Paget's Disease) that affect bone or wound healing.
  • In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
  • When intraoperative soft tissue coverage is not planned or possible.
  • Receiving treatment with medication interfering with calcium metabolism.
  • Has degenerative disc disease (DDD) related to a benign or malignant tumor.
  • Has history or presence of active malignancy.
  • Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
  • Is involved in active litigation relating to his/her spinal condition.
  • Has participated in an investigational study within 30 days prior to surgery for study devices.

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: MagnetOs Easypack Putty

Interventions

  • Procedure: Instrumented posterolateral spine fusion
  • Device; MagnetOs Easypack Putty

active comparator: Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed with local autograft bone

Interventions

  • Procedure: Instrumented posterolateral spine fusion
  • Device: Demineralized Bone Matrix or Fibers mixed with local autograft bone

Interventions

MagnetOs Easypack Putty

MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.

Demineralized Bone Matrix or Fibers mixed with local autograft bone

Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.

Primary outcome measure

  • Radiographic Fusion by CT Scan [ Time Frame: Month 12 ]

Central Contacts and Locations

Central contacts

Locations

The Regents of the University of California- Irvine Campus

Recruiting

Irvine, California, United States, 92697

Contacts

Michael Oh, MD

ohm2@hs.uci.edu

Corewell Health

Recruiting

Grand Rapids, Michigan, United States, 49503

Contacts

The Washington University

Recruiting

St Louis, Missouri, United States, 63130

Rothman Orthopaedic Institute

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Tennessee Orthopaedic Alliance

Recruiting

Nashville, Tennessee, United States, 37209

Principal Investigator:

Ryan Snowden, MD

University of Washington

Recruiting

Seattle, Washington, United States, 98104

Principal Investigator:

Christoph Hofstetter, MD

More Information

Sponsor

Kuros Biosurgery AG

Last update posted

Mar 20, 2026

Last verified

Nov, 2025

Keywords

  • Degenerative Disc Disease
  • Spine Fusion

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Kuros Biosurgery AG on 2026-03-20.